News Between Reporter

The recent announcement by the FDA expanding the indication of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) to include treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) is a significant milestone in the field of neurology. This decision provides hope to patients suffering from this rare and debilitating immune-mediated neuromuscular disorder by offering a new,